What Sustac forte Treats: Main Uses and Benefits

The therapeutic role of Sustac forte, containing an extended-release form of nitroglycerin, is commonly used for the prophylactic management of stable chest discomfort. The formulation is used for easing symptoms associated with the prevention of angina pectoris due to coronary artery disease.

---

Prophylaxis and Functional Support

Sustac forte is commonly used for the long-term prophylactic management of chronic stable angina pectoris, a condition defined by recurrent episodes of chest tightness, pressure, or pain. The medication's role is considered relevant to provide supportive relief for symptoms associated with recurrent episodes, which may assist with easing the overall symptom load. This sustained support is commonly used to help with symptoms that cluster into patterns requiring long-term supportive management, including recurrent chest discomfort and reduced exercise tolerance caused by exertion.

The therapeutic benefit may assist with maintaining a sense of stability when symptoms are more noticeable in daily routines and contributes to easing the symptomatic burden.

“This approach is relevant when supportive symptom management is appropriate, particularly to help patients cope more steadily with symptom fluctuations in their daily lives.”

Quick Fact: Support for Recurrent Anginal Symptoms Sustac forte supports patients by focusing on the prevention of stable chest discomfort, assists with maintaining functional stability and supports tolerance for physical activity.

Regulatory References

1. FDA DailyMed overview

Sustac forte, an extended-release nitroglycerin formulation, is allowed for use in adults for the prophylaxis of angina pectoris. Eligibility is strictly defined by regulatory criteria, with several groups designated as absolutely contraindicated or subject to conditional use.

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):	Adults for angina prophylaxis [Source 1.3]
Populations for whom use is not recommended:	Pediatric patients (Safety and effectiveness have not been established) [Source 2.3]
Populations for whom use is contraindicated:	Patients using PDE-5 inhibitors (e.g., sildenafil, tadalafil) or sGC stimulators (e.g., riociguat) [Source 1.4]. Patients with Severe Anemia, Increased Intracranial Pressure, Acute Circulatory Failure, or Shock [Source 1.5].

---

Age-Related and Conditional Eligibility

Age-related eligibility rules:	Older adults require caution due to potential decreased hepatic, renal, or cardiac function [Source 2.3].
Pregnancy and lactation eligibility status:	Conditional Use (Administer only if clearly needed in pregnant women or nursing mothers) [Source 1.3].
Eligibility-related restrictions:	Caution is required in patients with pre-existing hypotension or specific heart conditions like aortic stenosis, constrictive pericarditis, or hypertrophic cardiomyopathy [Source 1.5].

---

Official eligibility statements: The medicine is contraindicated when used with certain drug classes due to the risk of severe hypotension [Source 1.4]. Use in children is not established, and specific high-risk conditions, such as severe anemia, necessitate absolute exclusion [Source 4.2].

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Sustac forte (Nitroglycerin extended-release) as defined by government regulatory authorities.

Contraindicated Combinations

Co-administration with Phosphodiesterase-5 (PDE5) Inhibitors (including Sildenafil, Tadalafil, and Vardenafil) is contraindicated due to the risk of severe, life-threatening hypotension and syncope, a classification driven by pharmacodynamic potentiation. Similarly, Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat) are also contraindicated due to the potential for profound, additive hypotensive effects.

Timing and Drug-Drug Interactions

The prohibition on PDE5 inhibitors necessitates mandatory timing-based separation: at least 24 hours must elapse after the last dose of short-acting PDE5 inhibitors, and at least 48 hours after the last dose of Tadalafil, before nitrate administration can occur. The drug may have additive hypotensive effects when co-administered with other Antihypertensive Agents or Peripheral Vasodilators. Furthermore, oral administration of nitroglycerin is documented to increase the bioavailability of Ergot Derivatives (e.g., Ergotamine) by reducing their first-pass metabolism, which may increase the exposure risk of the ergot derivative.

Interactions with Other Substances

The consumption of alcohol is noted to cause or enhance hypotension due to additive vasodilatory effects, which may increase the frequency of associated symptoms. Intravenous administration of high-dose nitroglycerin is documented to reduce the anticoagulant effect of Heparin, requiring appropriate monitoring.

Nitric Oxide Pathway Activation and Vascular Relaxation

The action of Sustac forte begins at the cellular level, where its active component, Nitroglycerin (Glyceryl trinitrate, GTN), is converted by the enzyme Mitochondrial Aldehyde Dehydrogenase (mtALDH) into the signaling molecule Nitric Oxide ( NO). This NO activates the sGC-cGMP cascade, which subsequently induces the dephosphorylation of proteins within vascular smooth muscle cells. This core molecular mechanism results in significant smooth muscle relaxation across the vasculature.

---

Modulating Systemic Preload and Cardiac Workload

The widespread smooth muscle relaxation leads to vasodilation, which is most pronounced in the body's venous system, causing venous capacitance (venodilation) to increase. This physiological change reduces the amount of blood returning to the heart (preload), a dominant physiological consequence of the mechanism. The mechanism engages systems that regulate cardiac workload by reducing the volume the heart has to pump, resulting in a decreased cardiac work index.

---

Constraint: Bioactivation Dependency and Tolerance

The mechanism is constrained by its reliance on the proper function and availability of the mtALDH bioactivating enzyme. Chronic, continuous presence of the drug can impair the enzyme's ability to generate NO, a state known as nitrate tolerance. This mechanism limitation suggests that the mtALDH bioactivation system may require periods of low GTN exposure for its function to be restored.

How to Use Sustac forte: Administration Guidelines

This section describes the usage principles for the modified-release formulation of Glyceryl trinitrate.

---

Administration Scope

The medicine is designed for oral administration and must be swallowed whole. The modified-release tablet form is specifically not suitable for sublingual (under the tongue) use and should not be crushed or chewed, as this would compromise the intended sustained-release profile.

---

Dosing and Schedule

The dosage is generally individualized based on the patient's requirements, following the initial assessment by a healthcare professional. The usual regimen involves taking the medicine three times daily (TID). It is directed to be consumed between meals to align with the formulation's required absorption characteristics.

Typical Dosing Regimen (Adults)

The standard maintenance pattern involves one or two tablets per dose, utilizing the available strengths of either 2.6 mg or 6.4 mg of Glyceryl trinitrate.

---

Procedural and Population Constraints

This sustained-action oral form is not intended for treating an acute anginal episode due to its slow onset. Usage is reserved for long-term treatment prophylaxis. For older adults, dosage remains individualized based on patient need, while the medicine is not recommended for use in children. When discontinuing long-term therapy, the dosage must be reduced gradually over several days to ensure patient stability and prevent potential rebound effects.

Research evidence / Overview of studies for Sustac forte

Evidence for Use in Prophylactic Management of Chronic Stable Angina Pectoris

This section will summarize the research base describing the clinical evaluation of extended-release nitroglycerin, focusing on the findings from short-term, placebo-controlled, randomized trials and high-level systematic reviews.

Studies explored the use of this long-acting medication in the context of managing chronic stable angina pectoris, a condition characterized by fluctuating or episodic manifestations. Key evidence was derived from randomized controlled trials (RCTs). These short-term studies examined how this medication performed compared to an inactive treatment (placebo) or other therapies. The findings described group patterns observed in populations of adults.

---

Study Focus: Symptom Frequency and Functional Capacity

This part will detail the specific measures that researchers evaluated in the clinical trials, such as tracking the number of weekly angina episodes, consumption of acute-relief medication, and patient performance on standardized exercise tests.

The primary outcomes related to physical discomfort that research monitored were the frequency of angina episodes and the amount of short-acting (rescue) medication consumed. Research monitored changes in symptoms and reported data showing patterns related to angina frequency in the observed populations compared to controls. Research also examined outcomes reflecting daily functioning or activity level using standardized exercise tests. Data showed patterns related to measurements of total exercise duration and the time to the onset of symptoms in the studied groups.

---

Studies on Maintenance of Effect and Nitrate Tolerance

Studies explored the phenomenon known as nitrate tolerance, where the measured effect may become less pronounced over time if the medication is used continuously. Research examined different administration schedules to address this. Studies reported that measured functional outcomes were observed to be different when the medication was administered continuously without a specific period of discontinuation (nitrate-free interval). Conversely, research examining intermittent regimens reported patterns suggesting that observed functional outcomes were compared under these conditions.

Key Studies & References

1. NITROGLYCERIN EXTENDED-RELEASE CAPSULES - DailyMed (FDA Monograph)
2. World Health Organization Model List of Essential Medicines (WHO Essential Medicines List for Glyceryl Trinitrate)

Common questions about Sustac forte (FAQ)

Q: Is Sustac forte the same as regular Sustac?

A: Sustac forte is specifically a modified-release tablet formulation of Glyceryl trinitrate. This formulation is designed for a sustained-release of the active ingredient over several hours. This sustained action is the key feature that differentiates it from non-modified or rapid-onset forms of the medicine.

Q: What is the typical time frame for the effects of Sustac forte to be noticeable?

A: Official documents describe this medicine as having a slow onset of action. Because it is intended for long-term prophylaxis, meaning preventative use, its protective effects are designed to be sustained throughout the day rather than rapidly noticeable. It is not intended for immediate relief.

Q: Does the medicine come in different strengths?

A: Yes, regulatory documents confirm that the Glyceryl trinitrate extended-release tablet formulation is available in multiple strengths. The dosage a person uses is individualized by a healthcare professional.

Q: Are the side effects of Sustac forte generally considered temporary?

A: The most frequently reported side effect is a headache. Official documentation notes that this may be especially noticeable early in treatment and could potentially diminish with continued use as the body adjusts to the medicine.

Q: Are there any specific food or drinks that officially interact with Sustac forte?

A: Official labeling includes information that this formulation is designed to be taken between meals or on an empty stomach to support the intended absorption characteristics. Furthermore, regulatory documents explicitly note that the consumption of alcohol may enhance the potential for low blood pressure (hypotension).

Q: Does official research support the use of Sustac forte for long-term conditions?

A: Research described in regulatory documents examines its use for the long-term prophylactic management of chronic stable angina. These studies focus on both maintaining the intended effect and addressing the phenomenon of nitrate tolerance, where the effect might lessen over time.

Q: What is the difference in effect between Sustac forte and a quick-release version of the same medicine?

A: Sustac forte (modified-release) is used for long-term prevention (prophylaxis) due to its sustained, steady effect. In contrast, quick-release forms, such as sublingual tablets, are intended for the acute treatment of an angina episode because they provide a rapid but short-duration effect.

Q: Does the research suggest Sustac forte is effective across different demographics?

A: Clinical studies described in regulatory documents primarily involve the adult population. The labeling specifically includes a caution statement for use in older adults due to the potential for physiological changes and an increased risk of adverse effects like low blood pressure. Safety has not been established in pediatric patients.

Q: Is Sustac forte known to interact with blood thinners?

A: Official labeling documents an interaction with the anticoagulant Heparin, a type of blood thinner. Regulatory information notes that high-dose intravenous Nitroglycerin may reduce Heparin's anticoagulant effect, and this effect is generally associated with a need for clinical monitoring.

Q: What is the official recommendation for the duration of use of Sustac forte?

A: The medicine is officially indicated for the long-term prophylactic treatment of chronic stable angina. This therapeutic indication defines its purpose as a continuous, maintenance therapy, rather than a short-term course of treatment.

Q: Is the research evidence for Sustac forte considered strong by regulatory bodies?

A: Regulatory clearance and the inclusion of clinical study results in the official product label indicate that the evidence was deemed adequate to support the drug’s use for the stated prophylactic indication.

Q: Are there warnings about driving or operating machinery while using Sustac forte?

A: Official labeling includes a warning that common adverse effects such as dizziness and drowsiness may impair a person's ability to drive or operate machinery. This warning is particularly relevant when the treatment is started or if the dosage is adjusted.

Q: How long does the drug stay in the system after the last use?

A: Official regulatory documents contain data on the half-life of the active ingredient, Glyceryl trinitrate, and its active metabolites. This pharmacological information defines the drug's typical persistence in the body following administration.

Q: Can people with liver issues use Sustac forte?

A: Official labeling includes a caution related to use in older adults due to the potential for decreased hepatic (liver) function. Official labeling typically includes warnings or precautions related to use in patients with pre-existing liver impairment.

Q: Can people with kidney problems use Sustac forte?

A: Official labeling includes a caution related to use in older adults due to the potential for decreased renal (kidney) function. Regulatory documents often address the medicine's clearance route and any necessary precautions for patients with severe kidney impairment.

Q: Do official documents mention any potential for dependence with Sustac forte?

A: Official documents do not mention 'dependence.' However, they do specifically warn that abrupt discontinuation after long-term use is associated with an exacerbation of anginal symptoms (a rebound effect). Regulatory guidelines describe that the dosage must be reduced gradually to manage this potential rebound effect.

Q: What is the active ingredient's half-life as described in medical information?

A: The official pharmacokinetics section of the regulatory information contains the specific calculated values for the half-life of the active ingredient, Glyceryl trinitrate, which describes the rate at which the substance is eliminated from the body.

How to Store and Dispose of Sustac forte?

To maintain the stability of Sustac forte (Glyceryl Trinitrate) tablets, specific storage conditions mandated by regulatory authorities must be followed.

---

Storage Requirements

The medicine must be stored below 30 C and explicitly protected from heat, light, and moisture. It is mandatory to keep the tablets in their original container to maintain their integrity. As a critical safety measure, the product must be stored out of the sight and reach of children.

---

Disposal Instructions

Do not dispose of unused or expired tablets in household waste or wastewater. Disposal must be carried out in accordance with local requirements for medicinal waste to ensure proper environmental protection.